| Document |
Document Title |
|
WO/2013/022278A2 |
An N1-cyclic amine-N5-substituted phenyl biguanide derivative of Formula 1 or a pharmaceutically acceptable salt thereof, a method of manufacturing the same, and a pharmaceutical composition including the biguanide derivative or the phar...
|
|
WO/2012/165956A1 |
The invention is directed to a N, N-substituted guanidine compound or a salt or solvate thereof according to formula (1), R1RNC(NH)NR2R3, wherein R1 is methyl and R2 is hydrogen. R3 is a organic group comprising a halogen and thiomethyl ...
|
|
WO/2012/145932A1 |
The present invention relates to a novel process for preparing peramivir formula (I) or a pharmaceutically acceptable salt thereof, and to intermediates used therein.
|
|
WO/2012/121985A2 |
A method comprises forming a reaction mixture comprising a terephthalate polyester, a glycol comprising 2 to 5 carbons, and an amidine organocatalyst; and heating the reaction mixture at a temperature of about 120° C or more to depolyme...
|
|
WO/2012/082009A1 |
The invention relates to branched oligomers of hexamethylenediamine and guanidine of formula (I). The above-mentioned compounds can be used as active components of disinfecting agents. The invention also relates to the use of the above-m...
|
|
WO/2012/071766A1 |
A preparation method of L-arginine-α-ketoglutarate by direct crystallization from zymotic fluid is provided. The method includes: respectively pretreating L-arginine zymotic fluid and α-ketoglutaric acid zymotic fluid by flocculation, ...
|
|
WO/2012/071102A2 |
A method of buffering a chemical or biological composition, comprising adding to the composition an effective buffering amount of at least one protonated or un-protonated amine-quaternary ammonium compound having a general formula(CI)d w...
|
|
WO/2012/054701A2 |
The present invention is directed to a third generation form of creatine, specifically a creatine hydrochloride salt, that drives significant improvements in muscle development and recovery due to its enhanced bio-availability, while cau...
|
|
WO/2012/035346A1 |
Prodrugs of guanfacine, pharmaceutical compositions containing such prodrugs and a method for providing therapeutic benefit in the treatment of ADHD/ODD (attention deficient hyperactivity disorder and oppositional defiance disorder) with...
|
|
WO/2012/024233A2 |
In various embodiments, the present invention provides zwitterionic lipids, encapsulants incorporating these zwitterionic lipids and such encapsulants encapsulating one or more bioactive agent. An exemplary bioactive agent is a nucleic a...
|
|
WO/2012/003153A1 |
A curable composition comprises (a) at least one polydiorganosiloxane, fluorinated polydiorganosiloxane, or combination thereof comprising reactive silane functionality comprising at least two hydroxysilyl moieties; (b) at least one poly...
|
|
WO/2012/003160A1 |
A curable composition comprises (a) at least one inorganic or organic compound comprising reactive silane functionality comprising at least one hydrosilyl moiety; (b) at least one inorganic or organic compound comprising reactive silane ...
|
|
WO/2012/003108A1 |
A curable composition comprises (a) at least one polydiorganosiloxane, fluorinated polydiorganosiloxane, or combination thereof comprising reactive silane functionality comprising at least two hydroxysilyl moieties; (b) at least one poly...
|
|
WO/2012/003152A1 |
A curable composition comprises (a) at least one inorganic or organic compound comprising reactive silane functionality comprising at least one hydrosilyl moiety; (b) at least one inorganic or organic compound comprising reactive silane ...
|
|
WO/2011/157612A2 |
The invention relates to novel compounds derived from amino acids of formula (I) and also to cosmetic or dermatological compositions containing them and to their use as agents for treating human perspiration in a cosmetic composition. Th...
|
|
WO/2011/157611A2 |
The invention relates to novel compounds derived from amino acids of formula (I) and also to cosmetic or dermatological compositions containing them and to their use as agents for treating human perspiration in a cosmetic composition. Th...
|
|
WO/2011/156003A2 |
Novel peptide/peptoid oligomers are disclosed that have a formula represented by the following formula la or lb: The peptide/peptoid oligomers demonstrate the ability to inhibit fibnllization and oligomerization of Αβ and may be prepar...
|
|
WO/2011/122917A2 |
The present invention relates to an octahydrobinaphthol derivative which recognizes an amino acid and amino alcohol in a chiral-selective manner, converts L-amino acid into D-amino acid, and performs optical resolution on an amino acid a...
|
|
WO/2011/123856A1 |
Disclosed are neuraminidase inhibitor compounds and pharmaceutical compositions with improved bioavailability and/or improved efficacy and methods of treating influenza using the compounds and pharmaceuticals compositions.
|
|
WO/2011/109151A1 |
Ligand functionalized substrates, methods of making ligand functionalized substrates, and methods of using functionalized substrates are disclosed.
|
|
WO/2011/104667A1 |
The present disclosure describes about basic amino acid salts of polyphenolic compounds of formula (I) and composition thereof having improved physicochemical and pharmacological prosperities. Also describes process for preparation of th...
|
|
WO/2011/097717A1 |
Disclosed embodiments concern the synthesis and use of therapeutic compounds that for treating emerging flu strains and minimizing resistance to such strains. Methods for making the disclosed compounds concern using a base-mediated addit...
|
|
WO/2011/095027A1 |
Compounds of formula (I) or pharmaceutically acceptable salts thereof, and use for treating cancer thereof are disclosed, wherein, the definitions of X, Y, R1, R2 and n are described in description.
|
|
WO/2011/095428A1 |
The invention relates to hexaorgano guanidinium organocarbonates according to formula (I), to a method for the production of same, and to the use thereof. To this end, R1 to R5 denote alkyl, allyl, vinyl, benzyl, aryl or heteroaryl; wher...
|
|
WO/2011/083998A2 |
The present invention provides a biguanide derivative or pharmaceutically allowable salt thereof represented by Formula 1 with N1-N5 substitution, a preparation method thereof and a pharmaceutical composition containing the biguanide der...
|
|
WO/2011/083999A2 |
The present invention provides a biguanide derivative or pharmaceutically acceptable salt thereof represented by Formula 1 with N4-N5-substitutions, a preparation method thereof and a pharmaceutical composition containing the biguanide d...
|
|
WO/2011/075472A1 |
A method of producing arginine bicarbonate is provided including reacting an arginine slurry with a source of carbon dioxide gas under elevated temperature and low pressure to form a solution of at least 50% arginine bicarbonate, and rec...
|
|
WO/2011/075422A1 |
Methods of producing arginine bicarbonate solutions in very high concentrations including reacting an arginine slurry containing a first portion of arginine with a source of carbon dioxide gas at elevated pressure and temperature, adding...
|
|
WO/2011/061272A2 |
The invention relates to a process for reducing the residual amount of p-chloroaniline in chlorhexidine. Also, the invention relates to a process for preparing chlorhexidine, or a pharmaceutically acceptable salt thereof, which is free o...
|
|
WO/2011/056091A1 |
The invention relates to the field of pharmaceutical chemistry, specifically to processes for preparing biologically active substances (BAS), in particular creatine amides. What is proposed is a process for preparing creatine amides whic...
|
|
WO/2011/046597A2 |
A method is provided for the parallel identification of one or more metabolite species within a biological sample. The method comprises analyzing the sample to produce a spectrum containing individual spectral peaks representative of the...
|
|
WO/2011/043690A1 |
The invention relates to antiseptic means and to a method for producing the same, and can be used as a disinfecting means having a large application range in medicine, veterinary medicine, agriculture, etc. The method for producing bioci...
|
|
WO/2011/033296A1 |
Prodrugs of guanfacine with amino acids or short peptides,pharmaceutical compositions containing such prodrugs and a method for providing therapeutic benefit in the treatment of ADHD/ODD (attention deficient hyperactivity disorder and op...
|
|
WO/2011/025267A2 |
The present invention relates to metformin methanesulfonate, to a method for preparing same, to a pharmaceutical composition comprising same, and to a combined formulation comprising same. The metformin methanesulfonate of the present in...
|
|
WO/2011/025269A2 |
The present invention relates to metformin taurate, to a method for preparing same, to a pharmaceutical composition comprising same, and to a combined formulation comprising same. The metformin taurate of the present invention has superi...
|
|
WO/2011/025270A2 |
The present invention relates to a metformin caffeic acid salt, to a method for preparing same, to a pharmaceutical composition comprising same, and to a combined formulation comprising same. The metformin caffeic acid salt of the presen...
|
|
WO/2011/019348A1 |
Disclosed are creatine β-alaninate, compositions and formulations containing same, and methods of use therefor.
|
|
WO/2011/010013A1 |
The present invention relates to acyl guanidine derivatives modulating the hedgehog protein signaling pathway to be used as drugs, in particular for treating diseases involving a tissue dysfunction associated with a deregulation of the h...
|
|
WO/2011/008453A2 |
The present invention provides N-phosphonomethylglycine guanidine salts. The N-phosphonomethylglycine guanidine salts have improved herbicidal efficacy over glyphosate alone. The present invention also provides guanidine compounds and sa...
|
|
WO/2011/008054A2 |
The present invention provides metformin butyric acid salt, a method of preparing the same, and pharmaceutical compositions and combinations containing the same. The metformin butyric acid salt according to the present invention has an e...
|
|
WO/2011/008053A2 |
The present invention provides metformin propionate, a method of preparing the same, and pharmaceutical compositions and combinations containing the same. The metformin propionate according to the present invention has an excellent pharm...
|
|
WO/2010/132982A1 |
It is reported herein that certain muscle diseases and conditions, including forms of muscular dystrophy, are characterized by impaired insulin-dependent signaling in the muscle tissue, in essence, a form of insulin resistance. The prese...
|
|
WO/2010/133570A1 |
The present invention relates to flame retardant polymer compositions which comprise guanidine phenylphosphinates and mixtures with additional flame retardants.The compositions are especially useful for the manufacture of flame retardant...
|
|
WO/2010/100337A1 |
The present invention relates to novel prodrugs of metformin, their pharmaceutically acceptable salts, pharmaceutical compositions containing the prodrugs, and methods of using the prodrugs. In particular, the present invention relates t...
|
|
WO/2010/097604A2 |
A compound of formula I, or a pharmaceutically acceptable salt thereof, wherein - X1, X2 and X3 are each independently where Y is an alkylene, alkenylene or alkynylene group, each of which may be optionally substituted with one or more s...
|
|
WO/2010/094821A1 |
The invention relates to the use of vaginally-administered insulin-sensitizing agents for preventing and/or treating hyperandrogenism and/or polycystic ovarian syndrome and/or related disorders.
|
|
WO/2010/096123A2 |
The present invention is directed to novel amino acid prostaglandin salts and methods of making and using them.
|
|
WO/2010/092039A1 |
The invention relates to hexaalkylguanidinium salts of the general formula (I), wherein n = 2, 3, or 4 according to the charge of X; R1-R6 = organic groups; Xn- = tungstate (W10O23)4-, molybdate (Mo10O23)4-, silicon molybdate (SiMo12O40)...
|
|
WO/2010/093706A2 |
Provided herein is a method for chemically programmed vaccination. Methods include inducing a covalent-binding polyclonal antibody response in a subject and programming the polyclonal response with a targeting compound.
|
|
WO/2010/090305A1 |
Disclosed is an excellent agent for treatment or prevention of dementia, schizophrenia and the like, which has a serotonin 5-HT5A receptor modulating activity. An acylguanidine derivative represented by formula (I), wherein guanidine is ...
|
